Study of the dynamics of indicators of immune status in patients with breast cancer against the background of neoadjuvant chemotherapy

Background. In the structure of modern oncological diseases, one of the actual problems of oncology is breast cancer (BC), which ranks second among oncological pathologies in the world. Despite the preventive measures and successes achieved in the therapy of ВС, the incidence rate is constantly increasing. Analysis of data from the World Health Organization proved that ВС is the most common cancer in the world. The number of healthy life years (DALYs) lost to women with this diagnosis is greater than that of any other type of cancer in women worldwide. ВС occurs in all countries of the world in women of any age after reaching puberty, but the incidence rate increases in older age. Today, modern treatment of ВС remains a staged, multi-component process that requires an individual approach. Neoadjuvant polychemotherapy (NAPСT) is the main standard for locally advanced ВС. Carrying out neoadjuvant systemic therapy allows in vivo determination of tumor sensitivity to chemotherapeutic agents, identification of prognostic «markers», «reduction» of the stage of the oncological process and organ-sparing surgical intervention in this category of patients. However, the use of polychemotherapy (PCT) in ВС can lead to the appearance of side effects, the presence of which depends on the type of drug, the dose of the active substance, the duration of treatment and the characteristics of the patient’s immune status. Purpose – of the work is to study and analyze the data of immune parameters in patients with BC during a course of NAPCT, who were being treated at the Communal non-profit enterprise of the Kharkiv Regional Council «Regional Center of Oncology». Materials and Methods. An immunological study was conducted in 42 breast cancer patients aged 32–58 years. The average age of the patients was 44.8 ± 12.4 years. The control group consisted of 20 healthy individuals without signs of obvious acute and chronic somatic pathology. An immunological study was conducted in 42 breast cancer patients aged 32–58 years. The average age of the patients was 44.8 ± 12.4 years. The control group consisted of 20 healthy people without signs of obvious acute and chronic somatic pathology. The state of the systemic immune response was assessed by the population and subcellular state of peripheral blood lymphocytes. The study was conducted in the dynamics of treatment before the beginning of the 1st course (I period), after the last course (II period) of NAPHT. The material for the stud